Education
1989-1994 Bachelor, Medical College of Wuhan University
1996-1999 Master, SurgicalOncology, Medical College of Wuhan University
2002-2005 PhD, Surgical Oncology, Medical College of SunYat-Sen university
ClinicalInterests
Individualized precision treatments as well as comprehensivemultidisciplinary treatments, including surgery, chemotherapy, endocrinetherapy, radiotherapy, targeted therapy, and immunotherapy for different typesof breast cancer
Breast-conserving surgery, oncoplastic surgery, and breastreconstruction
Ultrasound-guided vacuum-assisted breast biopsy
Experience
2010-2011 Memorial Sloan Kettering Cancer Center(MSKCC) Visitingscholar
Honorsand Awards
2015 Guangzhou Best Breast doctor
2015 KBCF Scholarship Award, Global BreastCancer Conference
2017 Chinese Excellent Doctor
2019 National Top Doctor
Professional Memberships
Member, CSCO Council
Member, CSCO BC Standing Expert Committee
Member, Chinese Anti-Cancer Association Expert Committee
Vice-Chair, Breast Disease Branch of Guangdong Medical Association
Chair, Youth Committee, Breast Disease Branch of Guangdong MedicalAssociation
Member, Panel Review Committee, General Program of National NaturalScience Foundation of China
Publications
1. YangM, Fan Y, Wu ZY, Gu J, Feng Z, Zhang Q, Han S, Zhang Z, Li X, Hsueh YC, Ni Y,Li X, Li J, Hu M, Li W, Gao H, Yang C, Zhang C, Zhang L, Zhu T, Cheng M, Ji F,Xu J, Cui H, Tan G, Zhang MQ, Liang C, Liu Z, Song YQ, Niu G, Wang K.DAGM: A novel modelling framework to assess the risk of HER2-negative breastcancer based on germline rare coding mutations. EBioMedicine. 2021 Jun 19;69: 103446.
2. GongK, Song K, Zhu Z, Xiang Q, Wang K, Shi J. SWIM domain proteinZSWIM4 is required for JAK2 inhibition resistance in breast cancer. Life Sci.2021 Aug 15;279: 119696.
3. ZhangJ, Yang C, Lei C, Zhang Y, Ji F, Gao H, Yang M, Zhang L, Li J, Zhu T, Li W,Zhuang X, Wang K. Survival outcomes after breast-conservingtherapy compared with mastectomy for patients with early-stage metaplasticbreast cancer: a population-based study of 2412 patients. Breast. 2021 Aug;58: 10-17.
4. GaoHF, Wu Z, Lin Y, Song XY, Cao Y, Chen QJ, Zhang G, Fu P, Liu Z, Zhang LL, YangCQ, Yang M, Zhu T, Ji F, Li JQ, Cheng MY, Wang K.Anthracycline-containing versus carboplatin-containing neoadjuvant chemotherapyin combination with trastuzumab for HER2-positive breast cancer: the neoCARHphase II randomized clinical trial. Ther Adv Med Oncol. 2021 Apr 20;13: 17588359211009003.
5. Yang C, Lei C, Zhang Y, Zhang J, Ji F, Pan W, Zhang L, Gao H, Yang M, Li J, Wang K,Comparisonof Overall Survival Between Invasive Lobular Breast Carcinoma and InvasiveDuctal Breast Carcinoma: A Propensity Score Matching Study Based on SEERDatabase. Front Oncol 2020;10.
6. GaoHF, Li WP, Zhu T, Yang CQ, Yang M, Zhang LL, Ji F, Cheng MY, Li JQ, WangK. Adjuvant chemotherapy could benefit early-stage ER/PR positivemucinous breast cancer: A SEER-based analysis. Breast. 2020 Dec;54: 79-87.
7. LiWP, Gao HF, Ji F, Zhu T, Cheng MY, Yang M, Yang CQ, Zhang LL, Li JQ, Zhang JS, WangK. The role of adjuvant chemotherapy in stage I-III male breast cancer:a SEER-based analysis. Ther Adv Med Oncol. 2020 Sep 20;12: 1758835920958358.
8. LeiC, Yang C, Xia B, Ji F, Zhang Y, Gao H, Xiong Q, Lin Y, Zhuang X, Zhang L, ZhuT, Cheng M, Yang M, Wang K. Analysis of Tau Protein Expression inPredicting Pathological Complete Response to Neoadjuvant Chemotherapy inDifferent Molecular Subtypes of Breast Cancer. J Breast Cancer. 2020 Jan22;23(1):47-58.
9. ZhuangXS, Chen C, Liu ZY, Zhang LL, Zhou XZ, Cheng MY, Ji F, Zhu T, Lei CQ, Zhang JS,Jiang JY, Tian J and Wang K. Multiparametric MRI‑based radiomics analysis for the predictionof breast tumor regression patterns after neoadjuvant chemotherapy. Transl Oncol[in press].doi; 10.1016/j.tranon.2020.100831.
10. ChengMY, Zhuang XS, Zhang LL, Zhu T, Lin YF, Yang M, Ji F, Yang CQ, Gao HF, WangK. (2020). A nomogram to predict non-sentinel lymph node metastasis inpatients with initial cN+ breast cancer that downstages to cN0 afterneoadjuvant chemotherapy. J Surg Oncol. doi:10.1002/jso.25989.
11. LiWP, Zhu T, Hu MX, Yang M, Ji F, Gao HF, Yang CQ, Zhang LL, Cheng MY, Xu FP, WangK. Comparison of the efficacy and safety of the EC-T(epirubicin/cyclophosphamide followed by docetaxel) and TCb(docetaxel/carboplatin) neoadjuvant regimens in early TOP2A-normal stage II-IIIbreast cancer. NEOPLASMA accepted.
12. JiF, Yang CQ, Li XL, Zhang LL, Yang M, Li JQ, Gao HF, Zhu T, Cheng MY, Li WP, WuSY, Zhong AL, Wang K. Risk of breastcancer-related death in women with a prior cancer. Aging (Albany NY). 2020;12: 5894-5906.
13. YangCQ, Ji F, Gao HF, Zhang LL, Yang M, Zhu T, Chen MY, Li JQ, Wang K.The role of sharp dissection in nipple sparing mastectomy: a safe procedurewith no necrosis of the nipple-areolar complex. Cancer Manag Res. 2019;11:10223-10228.
14. LiuZH, Wang K, Lin DY, Xu J, Chen J, Long XY, Ge Y, Luo XL,Zhang KP, Liu YH, Xu FP. Impact of the updated 2018 ASCO/CAP guidelines on HER2FISH testing in invasive breast cancer: a retrospective study of HER2 fishresults of 2233 cases. Breast Cancer Res Treat. 2019;175(1):51-57.
15. LiuZ, Li Z, Qu J, Zhang R, Zhou X, Li L, Sun K, Tang Z, Jiang H, Li H, Xiong Q,Ding Y, Zhao X, Wang K, Liu Z, Tian J. Radiomics ofmultiparametric MRI for pretreatment prediction of pathologic complete responseto neoadjuvant chemotherapy in breast cancer: a multicenter study. Clin CancerRes. 2019;25(12):3538–47.
16. LiX, Yang M, Zhang Q, Fan Y, Zhu T, Chen F, Wang K.Whole Exome Sequencing inthe Accurate Diagnosis of Bilateral Breast Cancer:a Case Study. J Breast Cancer. 2019;22(1):131-140
17. XiongQ, Zhou X, Liu Z, Lei C, Yang C, Yang M, Zhang L, Zhu T, Zhuang X, Liang C, LiuZ, Tian J, Wang K.Multiparametric MRI-based radiomics analysis for prediction ofbreast cancers insensitive to neoadjuvant chemotherapy. Clin TranslOncol. 2019 Apr 11. doi: 10.1007/s12094-019-02109-8.
18. JiF, Xiao WK, Yang CQ, Yang M, Zhang LL, Gao HF, Lin YF, Zhu T, Cheng MY, Li WP,Pan WJ, Zhuang XS, Wang K. Tumor location of the central andnipple portion is associated with impaired survival for women with breastcancer. Cancer Manag Res. 2019 Apr 9;11:2915-25. doi:10.2147/CMAR.S186205.
19. LeiC, Wei W, Liu Z, Xiong Q, Yang C, Yang M, ZhangL, Zhu T, Zhuang X, Liu C, Liu Z, Tian J, WangK. Mammography-based radiomics analysis for predicting benign BI-RADScategory 4 calcifications. European Journal of Radiology. 2019
20. LiuC, Wang K, Li X, Zhang J, DingJ, Spuhler K, Duong T, Liang C, Huang C.Breast lesion characterization using whole-lesion histogram analysis with stretched-exponentialdiffusion model.J Magn Reson Imaging. 2018 ;47(6):1701-1710.
21. YangM, Xu J, Wang Q, Zhang AQ, Wang K. An obligatory anaerobicSalmonella typhimurium strain redirects M2 macrophages to the M1 phenotype.Oncol Lett. 2018;15(3):3918-3922
22. ZhangL, Huang Y, Yang C, Zhu T, Lin Y, Gao H, Yang M, Cheng M, Wang K.Application ofa carbon nanoparticle suspension for sentinel lymphnode mapping in patients with early breastcancer: a retrospective cohort study. World J Surg Oncol. 2018; 16(1):112.
23. GaoHF, Yang CQ, Cheng MY, Zhu T, Yang M, Zhang LL, Wang K.Prognostic Significance of Mesenchymal-Epithelial Transition in Triple-NegativeBreast Cancers. Clin Breast Cancer. 2018 May 7. pii: S1526-8209(17)30775-9.
24. ChenJY, Huang YJ, Zhang LL, Yang CQ, Wang K. Comparison ofOncoplastic Breast-Conserving Surgery and Breast-Conserving Surgery Alone: AMeta-Analysis. J BREAST CANCER. 2018; 21(3):321-329
25. ZhuT, Xu FP, Zhang LL, Zhang YF, Yang CC, Cheng MY, ChenFL, Wang K. Measurement of molecular biomarkers that predictthe tumor response in estrogen receptor-positive breast cancers afterdose-dense (biweekly) paclitaxel/carboplatin neoadjuvant chemotherapy.Oncotarget. 2017;8: 101087-101094
26. XuFP, Wang K, Xu J, Chen J, Zhang YF, WuHM, Zhang MH, Long XX, Luo XL, Zhang KP, LinDY, Liu YH. Impact of repeat HER2 testing after initial equivocal HER2 FISHresults using 2013 ASCO/CAP guidelines. Breast Cancer ResTreat. 2017；166(3):757-764.
27. LiuC, Wang K, Chan Q, Liu Z, Zhang J, He H, Zhang S, Liang C.Intravoxel incoherent motion MR imaging for breast lesions:comparison and correlation with pharmacokinetic evaluation from dynamiccontrast-enhanced MR imaging. Eur Radiol. 2016 Nov;26(11):3888-3898.
28. Zhu T, Liu CL, Zhang YF, Liu YH, Xu FP, Zu J, Zhang GC, Li XR, Liao N, WangK.A phase II trial of dose-dense (biweekly) paclitaxel plus carboplatinas neoadjuvant chemotherapy for operable breast cancer. Breast Cancer Res Treat. 2016;156(1):117-24
29. WangK, Deng QT, Liao N, et al. Tau expression correlated withbreast cancer sensitivity to taxanes-based neoadjuvant chemotherapy. TumourBiol. 2013;34(1):33-38
30. WangK, Zhou Q, Guo AL, Xu CR, An SJ, Wu YL．Autologous therapeutic dendritic cellsvaccine transfected with total lung carcinoma RNA stimulate CTL responsesagainst non-small cell lung cancer. Immunol Invest,2009,38( 7):665-680
